Glycosylated Hemoglobin A1 Predicts Risk for Symptomatic Hemorrhage After Thrombolysis for Acute Stroke
Stroke 44:2134-2138, Rocco, A.,et al, 2013
Symptomatic Intracranial Hemorrhage after Stroke Thrombolysis: The SEDAN Score
Ann Neurol 71:634-641, Strbian,D.,et al, 2012
Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009
Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis
Stroke 37:1205-1210, Montaner,J.,et al, 2006
Multiple Cerebral Microbleeds:MRI Marker of a Diffuse Hemorrhage-Prone State
J Neuroimaging 14:54-57, Chalela,J.A.,et al, 2004
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Intravenous Thrombolysis for Suspected Ischemic Stroke with Seizure at Onset
Ann Neurol 86:770-779, Polymeris, A.A.,et al, 2019
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic STroke
Stroke 47:581-641, Demaerschalk, B.M.,et al, 2016
IV Thrombolysis in very severe and severe ischemic stroke
Neurol 85:2098-2106, Mazyam, M.V.,et al, 2015
Is Intra-Arterial Thrombolysis Beneficial for M2 Occlusions? Subgroup Analysis of the PROACT-II Trial
Stroke 44:240-242, Rahme, R.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Thrombolysis Despite Recent Stroke
Stroke 44:1736-1738, Alhazzaa, M.,et al, 2013
The Types of Neurological Deficits Might Not Justify Withholding Treatment in Patients with Low Total National Institutes of Health Stroke Scale Scores
Stroke 43:782-786,625, Leira,E.C.,et al, 2012
Safety of Thrombolysis in Patients Over the Age of 80
The Neuroogist 18:99-101, Willey,J.Z.,et al, 2012
Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke
Stroke 42:1967-1970, Sarikaya, H.,et al, 2011
Established Treatments for Acute Ischaemic Stroke
Lancet 369:319-330, Khaja,A.M. &Grotta,J.C., 2007
Usefulness of Checking Platelet Count Before Thrombolysis in Acute Ischemic Stroke
Stroke 38:1639-1640, Cucchiara,B.L.,et al, 2007
Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Good Outcomes in Ischemic Stroke Patients treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms
Stroke 37:1332-1333, Baumann,C.R.,et al, 2006
Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen Activator
Arch Neurol 63:661-664, Bambauer,K.Z.,et al, 2006
Magnetic Resonance Imaging Criteria for Thrombolysis in Acute Cerebral Infarct
Stroke 36:388-397, Hjort, N., et al, 2005
Poor Outcomes in Patients Who Do Not Receive Intravenous Tissue Plasminogen Activator Because of Mild or Improving Ischemic Stroke
Stroke 36:2497-2499, Smith,E.E.,et al, 2005